14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CAPR vs KALV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CAPR vs KALV. Trailing 12-month operating profitability (CAPR 0.0% vs KALV -57.4%) and valuation multiples (CAPR 78.7x vs KALV 25.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.4B market capitalization and -57.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CAPR vs KALV Key Questions & Quantitative Answers
As of Nov 16, 2026, KalVista Pharmaceuticals, Inc. (KALV) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas KALV carries 55.1/100 (HOLD) at $27.00 (25.4x Forward P/E, -57.4% operating margin). Technically, CAPR sits in a Markup phase (RSI 51.3, CONSOLIDATION options structure) and KALV sits in a Markup phase (RSI 76.0, UNCLASSIFIED options structure).
KALV leads the Growth & Scale pillar: CAPR posts -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin), compared with KALV at +30.7% YoY revenue growth and +0.0% YoY earnings growth on $114M TTM revenue (51.1% gross margin, -57.4% operating margin). On trailing 12-month operating scale, CAPR generates $11M in USD-normalized revenue versus $114M for KALV. In operating R&D and SG&A reinvestment, CAPR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KALV.
KALV screens cheaper on headline valuation multiples. CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin), whereas KALV trades at 25.4x Forward P/E, 25.4x Trailing P/E, N/M PEG, and 12.6x EV/Revenue (-120.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAPR (-100.5% ROE) versus KALV (-190.2% ROE) capital efficiency.
In options market volatility and institutional positioning, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk). By comparison, KALV carries 88.9% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 26.28x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.85β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.